CAD enters digital mammography
Computer-aided detection software developed by R2 Technology can now be marketed as an integral part of the GE Senographe 2000D full-field digital mammography system, following FDA approval. This is the latest step in R2's pioneering efforts to make CAD
Computer-aided detection software developed by R2 Technology can now be marketed as an integral part of the GE Senographe 2000D full-field digital mammography system, following FDA approval. This is the latest step in R2's pioneering efforts to make CAD a routine part of medical practice. The FDA approved the company's ImageChecker, a stand-alone CAD workstation, in 1998 for use with film-based screening mammography. Three years later the FDA expanded approval to include its use with diagnostic mammograms. R2 has shipped more than 400 film and digital-based systems worldwide. More than three million women have had their mammograms interpreted with the aid of the ImageChecker CAD system. Nearly 300 Senographe 2000D systems have been installed in the U.S. All are upgradable to R2's CAD technology.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
